Lyka Labs Ltd (LYKALABS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500259 | NSE: LYKALABS | Pharmaceuticals & Drugs | Small Cap

Lyka Labs Share Price

83.50 2.46 3.04%
as on 05-Dec'25 12:17

Lyka Labs Ltd (LYKALABS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500259 | NSE: LYKALABS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Lyka Labs

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

yka Labs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
242.85
Market Cap:
289.2 Cr.
52-wk low:
78
52-wk high:
176

Is Lyka Labs Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Lyka Labs: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Lyka Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 10.5%9%-1.8%-0.7%-20.9%4.5%47.3%-1%2.5%8.4%-
Value Creation
Index
-0.3-0.4-1.1-1.1-2.5-0.72.4-1.1-0.8-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 76.47841.741.240.762.316480.6106135126
Sales YoY Gr.-2.2%-46.6%-1.2%-1.1%52.8%164%-51%32%26.6%-
Adj EPS 30.4-3.60.7-13.8-4.914-2.8-0.82.10.3
YoY Gr.--88.4%-1128.6%NA-2036.6%NANA-119.8%NANA-
BVPS (₹) 3833.434.134.86.61.515.519.227.337.837
Adj Net
Profit
6.70.8-10.12-39.4-13.940.2-8.5-2.57.61
Cash Flow from Ops. 10.320.26.818.3-11.55.876.56.93.13.3-
Debt/CF from Ops. 13.65.614.95-1228.11.710.418.411.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.5%27%-6.4%26.6%
Adj EPS -3.9%NA-46.7%NA
BVPS-0.1%42%34.6%38.6%
Share Price -3.4% 30.1% -15.1% -49.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
7.81.1-11.92.1-67.2-120.2164.5-14.1-2.96.50.9
Op. Profit
Mgn %
13.327.9-1.22.2-7.923.259.319.413.713.37
Net Profit
Mgn %
8.71-24.34.9-96.8-22.424.5-10.6-2.45.60.9
Debt to
Equity
1.61.51.10.97.336.72.91.20.60.30.1
Working Cap
Days
46130160263349323010124721421088
Cash Conv.
Cycle
-54-509112962-25-670657928

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Lyka Labs Ltd.

Standalone Consolidated
TTM EPS (₹) 0.3 0.6
TTM Sales (₹ Cr.) 126 137
BVPS (₹.) 37 28.3
Reserves (₹ Cr.) 96 65
P/BV 2.19 2.86
PE 242.85 140.68
From the Market
52 Week Low / High (₹) 78.01 / 175.95
All Time Low / High (₹) 8.46 / 267.20
Market Cap (₹ Cr.) 289
Equity (₹ Cr.) 35.7
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Lyka Labs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Lyka Labs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Lyka Labs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales57784241416216481106135
Operating Expenses 505642404448676592117
Manufacturing Costs2333668989
Material Costs34362222202431294353
Employee Cost 7101110121316172634
Other Costs 77757512101420
Operating Profit 822-11-31497161518
Operating Profit Margin (%) 13.3%27.9%-1.2%2.2%-7.9%23.2%59.3%19.4%13.7%13.3%
Other Income 12223323322
Interest 1317861926201252
Depreciation 3664881514126
Exceptional Items 1-21-1-28-1-5-7-00
Profit Before Tax 5-1-11-7-55-1860-13-111
Tax 0-0-0-90-420013
Profit After Tax 5-0-112-55-1440-13-28
PAT Margin (%) 8.4%-0.2%-26.0%4.2%-135.0%-23.2%24.3%-16.5%-2.1%6.1%
Adjusted EPS (₹)2.2-0.1-3.90.6-19.3-5.013.9-4.3-0.72.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 67749698194445990135
Share Capital 23222828292929313336
Reserves 43526870-10-2416285799
Minority Interest0000000000
Debt7273409113616182715534
Long Term Debt253557912615162634319
Short Term Debt4638361211102081215
Trade Payables302821221712981114
Others Liabilities 60678627372074413023
Total Liabilities 228242243238209197209179186206

Fixed Assets

Gross Block100939493141163172154153189
Accumulated Depreciation40713173968828898104
Net Fixed Assets 608681761029590665684
CWIP 3024263026241816231
Investments 63626262323232323232
Inventories797664871012
Trade Receivables2624303071018172640
Cash Equivalents 21008715961
Others Assets 40343534282427323433
Total Assets 228242243238209197209179186206

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 820718-11677733
PBT 5-1-11-7-55-1860-13-111
Adjustment 322121055343831178
Changes in Working Capital -0-0715-12-9-21-11-11-14
Tax Paid -0-1-0-01-1-1-0-1-3
Cash Flow From Investing Activity 5-5-3-300-47-9-13
Capex -5-5-3-3-1-1-66-9-13
Net Investments 00000000-0-0
Others 10000112110
Cash Flow From Financing Activity -13-15-4-1620-8-63-2035
Net Proceeds from Shares 00340200452527
Net Proceeds from Borrowing 010-3174280-50-46-18-24
Interest Paid -11-16-6-6-6-6-22-10-7-2
Dividend Paid 0000000000
Others -2-8-1-84-4-19-1035
Net Cash Flow 0-0-1-08-29-7-3-5

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)8.07-0.27-12.781.79-94.98-124.71163.37-25.69-3.047.31
ROCE (%)10.479.01-1.8-0.7-20.894.4547.25-1.022.548.38
Asset Turnover Ratio0.260.360.180.170.180.310.810.420.580.69
PAT to CFO Conversion(x)1.6N/AN/A9N/AN/A1.93N/AN/A0.38
Working Capital Days
Receivable Days1661092342661624831797490
Inventory Days59357159522914342830
Payable Days3722934193563592211221068185

Lyka Labs Ltd Stock News

Lyka Labs Ltd FAQs

The current trading price of Lyka Labs on 05-Dec-2025 12:17 is ₹83.50.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Lyka Labs stood at ₹289.2.
The latest P/E ratio of Lyka Labs as of 04-Dec-2025 is 242.8.
The latest P/B ratio of Lyka Labs as of 04-Dec-2025 is 2.19.
The 52-week high of Lyka Labs is ₹175.9 and the 52-week low is ₹78.01.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lyka Labs is ₹125.6 ( Cr.) .

About Lyka Labs Ltd

Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on  December 19, 1985.

The company is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs is committed to creating a better tomorrow for India. Maintaining a core competency in Lyophilization, allows Lyka Labs to supply Freeze Dried Drugs in sufficient quantities with the right quality. Lyka strives to manage this business in an ethical and transparent manner.

Lyka has 2 manufacturing facilities in Ankleshwar and Tarapur. There is also an R & D facility based in Chakala, Mumbai, and a corporate head office based in Andheri, Mumbai.

Plant located at Ankleshwar, Gujarat is one of the largest chemical Industrial estates in Asia. Located approx. 10 kms from the city of Bharuch, Gujarat. Ankleshwar is well connected and can be reached by road, rail or air from Mumbai, or by road and rail from Vadodara, or Ahmedabad.

Tarapur Plant is located in the MIDC Industrial Estate in Tarapur, District Thane, Maharashtra. Located approximately 80 kms from Mumbai City, and well connected by rail and road to Mumbai. 

Different business lines of the company:

  • Contract Manufacturing - Lyka undertakes manufacturing activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire manufacturing process, from sourcing of raw materials to manufacture to packaging, although Lyka also offers job work services where the raw materials are sourced by the client company. Their manufacturing processes are in line with world over best practices, as demonstrated by the ISO 9001:2002 Certification
  • Hospital Division - LYKA has forayed into marketing of products into hospitals/ institutions. To begin with, it has introduced a range of anti-infectives, which include systemic antimalarial, antifungal and antibacterials for serious infections. Apart from this, it has also introduced anesthetics, anti-ulcerants and steroid in parenteral dosage forms. On the anvil is the expansion of the range of the products in the above therapeutic segments as well as in the new therapeutic segments. The company also has plan to introduce products in solid dosage forms for hospitals / institutions.
  • Lyka Animal Health Care - Lyka Animal Healthcare Division within a short period has made strong presence in Indian Veterinary market with their quality innovative products. The animal healthcare division is managed and headed by veterinary professional with strong and dedicated team of field and in-house persons.
  • Generics - When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. Lyka markets branded generic products in the form of: -Tablets -Capsules -Ointments -Syrups Dry Powder and Liquids
  • Lyka BDR- Lyka manufactures and sells products to its Joint Venture company Lyka BDR. Lyka BDR is the largest seller of human and veterinary products in Sudan

Product range of the company includes:

  • Ampholyn Inj.  
  • Hydrolin Inj.   
  • Lyom Inj.   
  • Lypan Inj.   
  • Lypitaz Inj. 2.25g   
  • Lypitaz Inj. 4.5g   
  • Lyrab Inj.   
  • Lysunate Inj.  
  • Lysunate Tabs  
  • Lyvec Inj.   
  • Merojet Inj. 500mg   
  • Merojet Inj.1000mg   
  • Stropaz Inj.   
  • Thiolyn Inj. 500mg  
  • Thiolyn Inj.1000mg   
  • Vancolym Inj.   
  • Xolycef - SB Inj.   
  • Xolycef - TZ Inj.   
  • Xolycef Inj. 1000mg 
  • Zimtaz Inj. 

Achievements/ recognition:

  • ISO 9001:2000 certified
  • Recognized as in-house R&D Centre by Government of India, Ministry of Science & Technology, Department of Scientific and Industrial Research.
  • In 2011 the company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×